glp-1 agonist. Can one drug do it all? Reviewing the expanding clinical universe of agonists GLP-1 Drug Overdose

R(+)-Thioctic acid effects on oxidative stress and peripheral neuropathy in type II diabetic patients: preliminary results by electron paramagnetic resonance and electroneurography

Risk of esophageal and gastric cancer in patients with type 2 diabetes receiving glucagon-like peptide-1 receptor agonists (GLP-1 RAs): a national analysis

Emerging Role of GLP-1 Receptor Agonists for the Treatment of MASH Abstract: Emerging as a major global health concern, metabolic dysfunction-associated steatohepatitis (MASH) is closely linked to obesity, type 2 diabetes, and other metabolic disorders

Subsequently, we showed that GLP-1 induces satiety equally well in people with obesity [10]

M.CrociM.DanieleG.et al (2019)

297,299 When IB is phosphorylated and degraded, NF-B can move to the nucleus, activating multiple inflammation-related genes